I
Ivelina Gueorguieva
Researcher at Eli Lilly and Company
Publications - 72
Citations - 2889
Ivelina Gueorguieva is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Galunisertib & Population. The author has an hindex of 27, co-authored 65 publications receiving 2234 citations. Previous affiliations of Ivelina Gueorguieva include University of Manchester.
Papers
More filters
Journal ArticleDOI
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
Stephan Herbertz,J. Scott Sawyer,Anja Stauber,Ivelina Gueorguieva,Kyla Driscoll,Shawn T. Estrem,Ann Cleverly,Durisala Desaiah,Susan C. Guba,Karim A. Benhadji,Christopher A. Slapak,Michael Lahn +11 more
TL;DR: The use of a pharmacokinetic/pharmacodynamic model defined a therapeutic window with an appropriate safety profile that enabled the clinical investigation of galunisertib, and the past and current experiences with different pharmacological treatments that enabled it to be investigated in patients are summarized.
Journal ArticleDOI
First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
Jordi Rodon,Michael A. Carducci,Juan M. Sepulveda-Sanchez,Analia Azaro,Emiliano Calvo,Joan Seoane,Irene Brana,Elisabet Sicart,Ivelina Gueorguieva,Ann Cleverly,N. Sokalingum Pillay,Durisala Desaiah,Shawn T. Estrem,Luis Paz-Ares,Matthias Holdhoff,Jaishri O. Blakeley,Michael Lahn,José Baselga +17 more
TL;DR: On the basis of the safety, pharmacokinetics, and antitumor activity in patients with glioma, the intermittent administration of LY2157299 at 300 mg/day is safe for future clinical investigation and was safe, with no cardiac adverse events.
Journal ArticleDOI
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Alba A. Brandes,Antoine F. Carpentier,Santosh Kesari,Juan M. Sepúlveda-Sánchez,Helen Wheeler,Olivier Chinot,Lawrence Cher,Joachim P. Steinbach,David Capper,Pol Specenier,Jordi Rodon,Ann Cleverly,Claire Smith,Ivelina Gueorguieva,Colin Miles,Susan C. Guba,Durisala Desaiah,Michael Lahn,Wolfgang Wick +18 more
TL;DR: Galunisertib + lomustine failed to demonstrate improved OS relative to placebo + lmustine, and patients treated with galun isertib alone had fewer drug-related grade 3/4 adverse events compared with lomUSTine-treated patients.
Journal ArticleDOI
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Davide Melisi,Rocio Garcia-Carbonero,Teresa Macarulla,Denis Pezet,Gael Deplanque,M. Fuchs,Jörg Trojan,Helmut Oettle,Mark Kozloff,Ann Cleverly,Claire Smith,Shawn T. Estrem,Ivelina Gueorguieva,Michael Lahn,Al Blunt,Karim A. Benhadji,Josep Tabernero +16 more
TL;DR: Lower baseline biomarkers macrophage inflammatory protein-1-alpha and interferon-gamma-induced protein 10 were associated with galunisertib benefit, and future exploration of galun isertib in pancreatic cancer is ongoing in combination with durvalumab.
Journal ArticleDOI
A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis
Benjamin Ribba,Nicholas H. G. Holford,Paolo Magni,Iñaki F. Trocóniz,Ivelina Gueorguieva,P Girard,C Sarr,M Elishmereni,Charlotte Kloft,Lena E. Friberg +9 more
TL;DR: This selection of models with published mathematical equations aimed at describing the dynamics of tumor size in cancer patients following anticancer drug treatment will constitute the basis for the Drug Disease Model Resources (DDMoRe) repository for models on oncology.